# US 2009/0269409 A1 · Pharmaceutical compositions comprising eszopiclone

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269409 A1
- Document ID: US20090269409A1
- Status: Published application
- Kind: A1
- Application number: 12/428,818
- Filed: 2009-04-23
- Published: 2009-10-29
- Earliest claimed: 2008-04-24
- Inventors: Mukesh Kumar Garg; Parag Prakash Borde; Pradeep Kumar Gupta
- Web page: https://patentgrep.com/patent/US20090269409A1

## CPC

- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Pharmaceutical compositions comprising eszopiclone, including its pharmaceutically acceptable salts, hydrates, clathrates, solvates, polymorphs, and mixtures thereof. The invention also relates to processes for preparing the compositions and their methods of use.

## Claims

### Claim 1

A pharmaceutical composition comprising: a) eszopiclone or a salt thereof; and b) microcrystalline cellulose, lactose monohydrate, or a combination thereof.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, comprising both of microcrystalline cellulose and lactose monohydrate

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein a weight ratio of eszopiclone to a total of microcrystalline cellulose and lactose monohydrate ranges from about 1:5 to about 1:100.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, prepared using eszopiclone having an average particle size less than about 50 μm.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, prepared using eszopiclone having a particle size distribution where D90 is not more than about 10 μm, D50 is not more than about 8 μm, and D10 is not more than about 4 μm.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, having a moisture content less than about 8 percent by weight.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the 5-chloro-2-aminopyridine impurity content is less than about 2 percent of the label eszopiclone content.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the 5-chloro-2-aminopyridine impurity content is less than about 1 percent of the label eszopiclone content.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the 5-chloro-2-aminopyridine impurity content is less than about 0.5 percent of the label eszopiclone content.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the content of any single drug-related impurity is less than about 0.5 percent of the label eszopiclone content.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1 comprising eszopiclone, wherein the total drug-related impurity content is less than about 0.5 percent by weight of the label eszopiclone content.

### Claim 12

A pharmaceutical tablet composition comprising eszopiclone or a salt thereof and at least one pharmaceutically acceptable excipient, which composition does not contain calcium phosphate.

### Claim 13 (depends on 12)

The pharmaceutical tablet composition of claim 12, comprising: a) eszopiclone; b) a spray-dried composition of about 75 percent lactose monohydrate and about 25 percent microcrystalline cellulose, by weight; c) a disintegrant; d) a lubricant; and, optionally, e) a binder.

### Claim 14 (depends on 12)

The pharmaceutical tablet composition of claim 12, wherein eszopiclone is present in an amount less than about 15 percent by weight of the composition.

### Claim 15 (depends on 12)

The pharmaceutical tablet composition of claim 12, being prepared using wet granulation, dry granulation, or direct compression.

### Claim 16

A pharmaceutical tablet composition comprising eszopiclone and a spray-dried composition of about 75 percent lactose monohydrate and about 25 percent microcrystalline cellulose, by weight.

### Claim 17 (depends on 16)

The pharmaceutical tablet composition of claim 16, further comprising a disintegrant and a lubricant.

### Claim 18 (depends on 16)

The pharmaceutical tablet composition of claim 16, further comprising croscarmellose sodium and a lubricant.

### Claim 19 (depends on 16)

The pharmaceutical composition of claim 16, wherein the total drug-related impurity content is less than about 0.5 percent by weight of the label eszopiclone content.

### Claim 20 (depends on 16)

The pharmaceutical composition of claim 16, having a moisture content less than about 8 percent by weight.
